The combination drug, formerly known as LCZ696, is the first approved agent in the angiotensin receptor-neprilysin inhibitor (ARNI) class and exerts its effect within and beyond the renin-angiotensin system. Chemically, the agent consists of the angiotensin-receptor blocker valsartan affixed to the neprilysin inhibitor sacubitril.

Jul. 7th, 2015 approved by US FDA;

Oct. 19th, 2015 approved in Europe；

Jul. 28th, 2017 approved by CFDA

–Valsartan/sacubitril earns Class I recommendation in May 2016

The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) updated guidelines for pharmacological heart failure (HF) treatment, focusing specifically on 2 new agents: sacubitril/valsartan (Entresto) and ivabradine (Corlanor).

The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure have been published in the European Heart Journal and the European Journal of Heart Failure in conjunction with their presentation at the Heart Failure 2016 and the Third World Congress on Acute Heart Failure in Florence, Italy. Recommending that Entresto should replace ACEIs in patients who fit the PARADIGM-HF criteria......